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Abstract
Background: The presence of metabolic syndrome in patients with hypertension significantly increases the risk of
cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the epidemiological and economic
burden to the health service of metabolic syndrome in patients with hypertension in three European countries in
2008 and 2020.
Methods: An age, sex and risk group structured prevalence based cost of illness model was developed using the
United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define metabolic
syndrome. Data sources included published information and public use databases on disease prevalence, incidence
of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany,
Spain and Italy.
Results: The prevalence of hypertension with metabolic syndrome in the general population of Germany, Spain
and Italy was 36%, 11% and 10% respectively. In subjects with hypertension 61%, 22% and 21% also had metabolic
syndrome. Incident cardiovascular events and attributable mortality were around two fold higher in subjects with
metabolic syndrome and prevalence of type 2 diabetes was around six-fold higher. The economic burden to the
health service of metabolic syndrome in patients with hypertension was been estimated at €24,427, €1,900 and
€4,877 million in Germany, Spain and Italy and forecast to rise by 59%, 179% and 157% respectively by 2020. The
largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular
events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with metabolic
syndrome compared to those without and rose incrementally with the additional number of metabolic syndrome
components present.
Conclusion: The presence of metabolic syndrome in patients with hypertension significantly inflates economic
burden and costs are likely to increase in the future due to an aging population and an increase in the prevalence
of components of metabolic syndrome.
Background
High blood pressure is a leading cause of death and dis-
ability causing 13.5% of the world’s premature death
and 6% of its disability. Half of all strokes and ischemic
heart disease can be attributed to high blood pressure
[1]. This situation shows no sign of abating. Obesity, a
major risk factor for hypertension, has reached pan-
demic proportions [2] and research shows that around
two thirds of the prevalence of hypertension is directly
attributable to obesity [3]. Along with obesity, other
independent cardiometabolic abnormalities, such as
dyslipidaemia, hypertriglyceridaemia and glucose
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together. Such groupings of risk factors for cardiovascu-
lar disease in the same hypertensive individual occur
together more often than would be expected by chance
alone, giving rise to a clinical entity that has been
termed metabolic syndrome (MetS) [4]. The syndrome
has been shown to significantly increase the risk of car-
diovascular disease, type 2 diabetes and mortality [5-8].
In patients with hypertension it doubles the relative risk
of cardiovascular disease [9-11] and triples the relative
risk of type 2 diabetes [12]. Moreover, the risk increases
with the number of MetS components present [10,13].
As there are 16 different conceivable combinations of
risk factors that could be diagnosed as MetS not all can
be weighted equally in terms of their impact on risk and
for some combinations this increase in risk is controver-
sial. However, what is known for sure is that the coexis-
tence of hypertension disproportionately increases the
risk of cardiovascular disease [14].
However, there is much debate as to whether MetS
should be treated as a clinical entity in general practice
or whether physicians should concentrate on treating
individual risk factors. The primary purpose for diagnos-
ing MetS in general practice is to identify patients who
are at high long-term risk of developing cardiovascular
disease and type 2 diabetes and who require lifestyle
and/or pharmacological therapies to reduce this risk.
Recent European guidelines on the management of
patients with arterial hypertension consider those with
hypertension and MetS as a special condition suggesting
a different therapeutic approach compared to patients
with hypertension alone [15]. Such recommendations
are based on a number of evidence-based observations.
In a position statement the European Society of Hyper-
tension pointed out that in patients with hypertension
and MetS the overall cardiovascular risk may be greater
than the sum of its identifiable components and that
MetS components are often defined by values lower
than those defined in various individual risk factor
guidelines which may lead to many patients with high
cardiovascular risk not being identified [16]. They also
point out that MetS risk factors are relatively easily
identified in clinical practice.
The clinical utility of diagnosing MetS in general prac-
tice has been hampered by the inconsistency of the
diagnostic criteria available. Some definitions appear to
be better than others at identifying high risk patients in
Europe. In studies using both the International Diabetes
Federation criteria and those developed by the United
States Adult Treatment Panel III of the National Cho-
lesterol Education Program (ATP III) a much higher
prevalence of MetS was identified by the International
Diabetes Federation criteria [17,18] but these criteria led
to much lower predictive power for coronary events
than the ATP III criteria [19]. This suggests that cur-
rently the ATP III criteria are the most appropriate for
European populations given that excessive over-diagnos-
ing of the syndrome would subject the health service to
unnecessary budget pressures.
Relatively little is known about the epidemiological
burden of MetS in patients with hypertension in the
general population in Europe. Using ATP III criteria,
European population studies suggest that the prevalence
is around 8% to 13% [20-22]. The reported proportion
of hypertensive patients that have MetS is wide-ranging.
Population-based studies suggest the proportion is
around 20% to 40% [20-23]. Primary care studies report
that a fifth and up to just over a half of hypertension
patients can be diagnosed with MetS [13,17,24-27].
No studies have assessed the economic burden of
MetS in patients with hypertension. In order to fill this
gap this study aims to model the health care costs of
hypertension in three European countries (Germany,
Spain and Italy) in 2008 and 2020 and to assess how the
consequences of MetS in terms of associated type 2 dia-
betes and the increase in cardiovascular events impacts
on this economic burden.
Methods
Overview
This study uses a prevalence-based approach that com-
bined the demographics of the population with hyper-
tension and MetS prevalence rates, incidence of
cardiovascular disease, prevalence of type 2 diabetes and
healthcare costs into a cost of hypertension and MetS
model. A comprehensive literature review was con-
ducted to identify inputs and data sources included
national surveys, IMS Health Pharmaceuticals Sales data
and published information. The model and the assump-
tions used have been described in detail elsewhere [28].
Briefly we developed a prevalence-based model from
the perspective of the health service (Figure 1). MetS
was defined according to modified ATP III criteria,
where an individual is defined as having MetS if they
have three out of five diagnostic criteria: Abdominal
obesity (waist; males > 102 cm, females > 88 cm), hyper-
tension (≥140/90 mm Hg), low high-density lipoprotein
(HDL) cholesterol (males <40 mg/dL, females <50 mg/
dL), high triglycerides (≥ 150 mg/dL) and impaired fast-
ing glucose (≥ 110 mg/dL or known diabetes) [29]. We
modified the criteria in relation to blood pressure from
≥135/85 mm Hg to ≥140/90 mm Hg for two reasons;
first all epidemiological publications and databases used
to develop the model defined hypertension as blood
pressure of ≥140/90 mm Hg and second, because cur-
rent European and U.S. guidelines use this definition as
the treatment threshold for antihypertensive medication
[15,30].
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and Italy over the age of 20 years. Two sets of risk
groups were defined, totalling seven risk categories. Risk
was stratified first into two categories - those patients
with hypertension and MetS and those without - where
MetS was indicated by the hypertensive individual hav-
ing at least two other ATP III criteria, and second into
five risk categories - those patients with hypertension
only, hypertension plus one other ATP III criteria,
hypertension plus two other, hypertension plus three
other and hypertension plus four other ATP III criteria
(Figure 1). In order to breakdown the hypertension
population data into these risk groups we analysed the
United States National Health and Nutrition Examina-
tion Survey (NHANES) public use database (2000) to
assess the conditional structure for the five components
of MetS and applied this conditional structure to coun-
try-specific prevalence data.
Data sources
Prevalence data were sourced from a national survey in
G e r m a n y[ 3 1 ]a n dp u b l i s h e de pidemiological studies in
Spain [17,32] and Italy [22,33]. In order to estimate the
future prevalence up to 2020 compound annual growth
rates (CAGRs) were derived from the literature [34] or a
multiyear evaluation of the NHANES public use
database.
E a c hr i s kg r o u pw a sd i v i d e di n t ot h o s ew h or e c e i v e
antihypertensive drug treatment and those who don’t.
For the treated group the proportion and cost of hyper-
tensive subjects treated with each antihypertensive drug
class (monotherapy and combination therapy for
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Figure 1 Schematic representation of the burden of illness model.
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converting enzyme (ACE) inhibitors, calcium channel
blockers, diuretics and beta-blockers) were derived from
an analysis of IMS Health pharmaceutical national sales
data for all main antihypertensive drug classes pre-
scribed in 2007 to patients with an ICD-10 code for
hypertension. Treated patients were also assumed to
have associated costs for primary care visits to the clinic
for check-ups, tests and assessment of hypertensive
medication which were derived from country specific
publications [35-37]. For the treated group the model
took into account the differential adherence rate [38]
and relative risk of treatment-related new onset diabetes
between the drug classes [39].
For both treated and untreated patients the incidence
of cardiovascular events and prevalence of type 2 dia-
betes and their associated costs were estimated. Cardio-
vascular events included acute myocardial infarction,
congestive heart failure, unstable angina, stroke and
death. Incidence and costs of events were derived from
the literature [11,13,40-45]. The prevalence of type 2
diabetes in the hypertensive population was derived
from a European national survey [31] and costs derived
from published country-specific data [46].
The cost data in the model takes the viewpoint of the
health service and includes hypertension drug costs,
management of hypertension in primary care and costs
associated with the treatment and management of cardi-
ovascular events and type 2 diabetes. The cost of each
of these elements was calculated by multiplying the
quantity of the resource used or the number of events
with the unit price. All costs were inflated to 2008
prices and presented in Euros.
Analyses
The burden of illness model was created in Access. The
Access model generated epidemiological numbers and
costs which were then exported to excel for analysis.
The model was quality controlled by cross-checking epi-
demiological and cost data with other published reports.
To address uncertainty around the mean in the overall
cost of illness estimate, we conducted a univariate sensi-
tivity analysis, where one factor at a time was varied
while keeping all other factors constant at their base-case
value. We assessed the impact on cost-of-illness of; only
including incident rather than prevalent type 2 diabetes,
varying the continuation rate, drug cost, cardiovascular
cost and type 2 diabetes cost by plus and minus 20%; and
applying a discount rate of 3% to future costs.
Results
Prevalence and risk groups
The prevalence of hypertension with MetS in the gen-
eral population of Germany, Spain and Italy was 36%,
11% and 10% respectively in 2008. In Germany of all
subjects with hypertension over half (61%) complied
with the ATP III criteria for MetS. In Spain and Italy
this proportion was much lower with 22% and 21%
respectively. By 2020 the proportion of the hypertensive
population with MetS was forecast to increase to 78%,
45% and 43% in Germany, Spain and Italy respectively
giving a prevalence in the general population of hyper-
tension with MetS of 48% in Germany and 22% in Spain
and Italy. Germany had a higher proportion of hyper-
tensive subjects with three or four other components of
MetS (36%) compared to Spain (8%) and Italy (7%) (fig-
ure 2).
Figure 3 outlines the prevalence of each individual
MetS component in patients with hypertension in 2008
and 2020. The most prevalent component was abdom-
inal obesity which reached a prevalence of 62%, 40%
and 44% in hypertensive patients in Germany, Spain and
Italy respectively in 2008. This was followed by high
tryiglycerides, and then impaired fasting glucose. All
MetS components were forecast to rise with the preva-
lence of abdominal obesity and impaired fasting glucose
increasing the most.
Consequences of disease
The incidence of cardiovascular disease and mortality
was around two-fold higher in hypertensive subjects
with MetS compared to those without in all three coun-
t r i e s .T h ep r e v a l e n c eo ft y p e2d i a b e t e sw a sa r o u n ds i x
fold higher in subjects with MetS (table 1). The inci-
dence of cardiovascular disease and mortality and the
prevalence of type 2 diabetes increased incrementally
with each additional component of MetS. The total
number of cardiovascular events, deaths and cases of
type 2 diabetes are forecast to rise over 100% in Spain
and Italy respectively between 2008 and 2020 and by
around 50% in Germany (table 1).
Costs
Table 2 details the total annual cost-of-illness of hyper-
tension with and without MetS in 2008 and 2020 in
Germany, Spain and Italy. Total annual costs of hyper-
tension with MetS amounted to €24,427, €1,909 and
€4,877 million respectively in Germany, Spain and Italy
in 2008. These costs represented 82%, 42% and 45% of
the total annual costs of hypertension. By 2020, keeping
costs set at 2008 prices, these annual costs of hyperten-
sion with MetS were forecast to rise by 59%, 179%,
157% in Germany, Spain and Italy respectively (table 2).
The largest component of the total annual cost of
hypertensive patients with MetS was the treatment and
management of the consequence of disease rather than
the management of hypertension itself including physi-
cian and drug costs. Prevalent type 2 diabetes and
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of total costs respectively in Germany in 2008 (figure 4).
In Spain these proportions were 50% and 37% and in
Italy were 71% and 17%. Hypertension drug costs and
physician costs relating to the management of hyperten-
sion constituted the smallest proportion of total costs in
all countries (figure 4).
Mean annual costs per hypertensive patient were
around three-fold higher in subjects with MetS com-
pared to those without and rose incrementally with the
additional number of MetS components present (figure
5). The greatest increment in per patient costs was
from no metabolic components present to one where
there was a two-fold increase after which the costs
increased by around 1.2 to 1.8 fold with each additional
component.
Sensitivity analysis
A number of sensitivity analyses were conducted (table
3). The total annual cost-of-illness of hypertension, with
and without the presence of MetS did not vary signifi-
cantly from the base case, with the exception of only
including cases of incident or new onset diabetes rather
than prevalent type 2 diabetes. In particular, in Germany
by only including incident type 2 diabetes reduced the
cost of hypertension with MetS from €24,427 million to
€8,753 million. There was also a greater degree of varia-
tion in total costs when cardiovascular and type 2
Figure 3 Prevalence of individual components of MetS in patients with hypertension; 2008 and 2020.
Figure 2 Proportion of the hypertensive population > 20 years within each risk group; 2008-2020.
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when drug costs and continuation rates were varied. We
also assessed the impact of applying a discount rate of
3% to future costs. This would reduce the total annual
cost of hypertension in 2020 from €42,769 million
to €29,997 million in Germany; from €8,180 million to
€5,737 million in Spain; and from €18,710 million
to €13,123 million in Italy.
Discussion
The results of this modelling study suggest that the pre-
sence of MetS in patients with hypertension significantly
inflates the cost of illness due to the increase in cardio-
vascular events and cases of type 2 diabetes. These costs
rise incrementally with the additional number of MetS
components present. In Germany hypertensive patients
with MetS account for over 60% of all hypertensive
patients and contribute to 80% of the costs. In Spain
and Italy they account for nearly a quarter of the hyper-
tensive population and contribute to nearly half of the
costs. The much higher prevalence in Germany can be
explained by the country having one of the highest rates
of abdominal obesity in Europe [47]. Mean annual costs
per patient for those with MetS are two to three times
higher than for those without. Antihypertensive drug
costs make up less than 10% of overall costs of care in
this high risk patient group with the management and
treatment of cardiovascular events and type 2 diabetes
accounting for the majority of costs.
These costs are set to rise in the future as the propor-
tion of the population over the age of 50 years grows
and the prevalence of the components of MetS
increases. The most prevalent component of MetS in
patients with hypertension is abdominal obesity which
has reached epidemic proportions in Europe and cur-
rently shows no sign of slowing down [48].
This study used a prevalence-based modelling
approach to estimate cost-of-illness and therefore is sub-
ject to a number of assumptions. Although efforts were
made to ensure the best sources of data available to
date were used in the model, as the published literature
in this area is still relatively limited and national data-
bases do not provide all appropriate data required to
estimate epidemiological burden [49], there were a num-
ber of data gaps. As with all models that require some
assumptions to be made an element of caution is
required when interpreting the results. The assumptions
used in this model are described in detail elsewhere
[28]. For example we used a United States database to
develop our conditional probability matrix which pro-
vided data on the probability of hypertensive subjects
having no other MetS components, one, two, three or
Table 1 Annual number and event rate per 1,000 hypertensive patients of incident cases of cardiovascular disease,
mortality and prevalent cases of type 2 diabetes; 2008 and 2020
Germany Spain Italy
No. events Event rate* No. events Event rate* No. events Event rate*
Annual incidence of cardiovascular events
2008
MetS† 583,500 27 74,600 25 103,300 24
No MetS‡ 188,500 14 134,000 13 202,500 13
2020
MetS† 889,500 29 208,300 27 267,800 25
No MetS‡ 124,400 14 132,200 14 189,900 13
Annual incidence of mortality
2008
MetS† 64,000 3.00 14,800 2.74 11,300 2.64
No MetS‡ 20,600 1.49 8,200 1.45 22,400 1.40
2020
MetS† 97,800 3.17 22,800 2.90 29,300 2.78
No MetS‡ 13,600 1.52 14,500 1.50 20,800 1.50
Annual prevalence of type 2 diabetes
2008
MetS† 5,287,600 248 834,500 281 1,313,300 308
No MetS‡ 627,300 45 515,100 51 823,700 52
2020
MetS† 8,676,100 281 2,364,500 301 3,390,200 322
No MetS‡ 510,300 57 703,400 73 1,021,600 71
* Event rate per 1000, † hypertension patients with MetS, ‡ hypertension patients without MetS.
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in each age and sex group. These probabilities were
applied to country-specific prevalence data to break-
down individuals into each risk group. We have no rea-
son to assume that such conditional structures would be
different between the U.S. and the three European coun-
tries as the clustering of individual MetS risk factors is
unlikely to be significantly different.
Our estimates of the economic burden of MetS in
patients with hypertension are on the conservative side
for a number of reasons. First, no data were available to
distribute costs of antihypertensive medications across
risk groups and therefore costs have been distributed
evenly across each of the five risk groups. Data suggest
that the quantity and type of antihypertensive medica-
tion does differ between those with and without MetS.
Those with MetS use significantly more ACE-inhibitors
and ARBs and in general use antihypertensive drugs sig-
nificantly more frequently than those without the syn-
drome [17,50]. A redistribution of costs accounting for
this would not increase the overall drug costs, but
would increase the proportion of drug costs that are
attributable to MetS. Second, the number of cardiovas-
cular events occurring in the population was predicted
using data derived from a population initially free of
cardiovascular disease (a proportion of the population
had type 2 diabetes). The model therefore does not take
into account the costs attributable to those hypertensive
subjects with MetS and established cardiovascular dis-
ease, which would increase the total cost of illness.
Finally, we only included healthcare costs in our model.
Including costs relating to the loss in productivity due
to morbidity or premature mortality would inflate cost-
of-illness estimates by between 1.28 fold [51] and 10
fold [52]. Such wide estimates reflect the different meth-
odologies used to calculate productivity losses.
Future prevalence estimates and costs are based on
projected changes in the demographics of each country
Table 2 Annual cost-of-illness (Euros, millions) of
hypertension and the proportion of costs attributable to
MetS; 2008 and 2020
Annual costs
Drug
1 Physician
2 CVD
3 Type 2
diabetes
4
Total
2008
Germany
With MetS† 628 1,952 5,265 16,582 24,427
Without
MetS‡
407 1,264 1,703 1,967 5,341
Spain
With MetS 116 126 699 968 1,909
Without
MetS
397 432 1,256 597 2,682
Italy
With MetS 258 330 817 3,472 4,877
Without
MetS
958 1,222 1,599 2,178 5,957
2020
Germany
With MetS† 901 2,820 8,026 27,208 38,955
Without
MetS‡
270 817 1,124 1,600 3,811
Spain
With MetS 301 333 1,952 2,743 5,329
Without
MetS
384 412 1,240 816 2,852
Italy
With MetS 629 813 2,117 8,964 12,523
Without
MetS
877 1,109 1,500 2,701 6,187
CVD-cardiovascular disease.
† hypertension patients with MetS, ‡ hypertension patients without MetS.
1Drug costs relate to antihypertensive treatments only,
2physician costs relate
to visits to the clinic as a result of hypertension for check-ups and assessment
of antihypertensive medication,
3CVD costs relate to ambulatory and
hospitalisation costs for the management of each event,
4type 2 diabetes
costs relate to the management of each patients and the costs of non-CVD
related complications.
Figure 4 Proportion of drug, physician, cardiovascular and type 2 diabetes costs to total annual costs for patients with hypertension
and MetS; 2008.
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based on historical data trends. However, such forecasts
do not take into account the potential impact of policy
directives aimed at reducing the risk of developing one
of the five MetS components. Future public health
incentives will have an impact on future prevalence and
costs however, these policies will be working against an
increase in prevalence brought about by the aging popu-
lation. The burden of illness in the future will therefore
be dependent on how effective public health policies
and guidelines are at preventing and treating MetS.
A handful of studies have assessed the prevalence of
hypertension in patients with MetS, but none to date
have assessed its economic impact. Previous population
studies using ATP III criteria have shown that approxi-
mately 20% to 40% of the hypertensive population has
MetS [20-23] giving rise to a prevalence in the general
population of hypertension and MetS of 8% to 14%
[20-22]. These estimates are similar to our estimates for
Spain and Italy. Much higher estimates of the propor-
tion of hypertensive subjects that have MetS are
reported in primary care studies where the variation can
be explained in part by the different sub-populations
studied [13,17,24,25,27,53].
This study has highlighted the additional resource
implications of hypertensive patients with MetS and the
need to manage these patients effectively according to
European guidelines to reduce the risk of cardiovascular
disease and type 2 diabetes. However, a previous Eur-
opean study reported that fewer than 30% of treated
hypertensive patients had their blood pressure con-
trolled to levels recommended by European guidelines
and that uncontrolled hypertension was strongly asso-
ciated with MetS [27]. Not achieving recommended tar-
get levels of blood pressure control leaves these patients
with elevated levels of risk. The study highlighted the
importance of considering the patient’s entire cardiome-
tabolic profile when considering appropriate treatment
rather than focusing solely on blood pressure targets
alone [27].
European guidelines advocate that appropriate man-
agement of patients with hypertension should be based
on their blood pressure level and overall cardiovascular
risk profile. Guidelines recognise that due to the differ-
ent mode of action of these classes, some drug groups
are likely to offer greater benefits to different subgroups
of patients [15,54,55]. In a recent reappraisal of guide-
lines on hypertension management, they suggest that
drug choice should take into account contraindications
as well as favourable effects in specific clinic settings.
The guidelines do not recommend specific drugs for the
treatment of hypertensive patients with metabolic syn-
drome, but do point out that ‘there is no doubt that
beta-blockers and diuretics (especially when combined
together) have adverse metabolic effects and facilitate
new onset diabetes in predisposed patients such as those
with metabolic syndrome or impaired glucose tolerance.’
They go on to point out that there is still controversy
over whether drug-induced new onset diabetes carries
the same negative prognosis as naturally occurring dia-
betes [55]. In patients with diabetes the guidelines sug-
gest that combination treatment is usually required and
that ‘a renin-angiotensin receptor blocker should always
be included because of the evidence of its superior
Figure 5 Mean annual costs (Euros) per hypertensive patient according to the number of components of MetS; 2008.
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nephropathy.’
Evidence suggests that newer antihypertensive medica-
tions are associated with a reduced risk of incident dia-
betes [39] and that they are also associated with better
adherence to therapy [38,56,57]. Although meta-analyses
suggest antihypertensive drugs have a similar effect on
reducing cardiovascular events [58], there is some evi-
dence to suggest that newer antihypertensive medica-
tions may lead to a greater reduction in the risk of first
hypertension-related cardiovascular or diabetic event
[57]. In addition, it has been recently demonstrated that
obese hypertensive patients under drug-based weight
loss therapy show significantly better weight reduction
and improvement of insulin resistance when treated
with newer antihypertensive medications compared to
the older blood pressure lowering drugs (beta blocker,
diuretics) [59]. Of the newer antihypertensive treatments
ARBs have been found to be associated with the highest
level of adherence [38,56,57] and the lowest association
with incident diabetes [39]. Furthermore specific ARBs
have also demonstrated favourable metabolic effects not
present in other ARBs or ACE-inhibitors [60].
Following such guidelines which recommend the
aggressive management of these high risk patients with
a combination of lifestyle interventions to treat the
MetS components present in the hypertensive individual
and to prevent the onset of additional components is
likely to lead to a significant reduction in costs of care.
Newer antihypertensives lead to better control of blood
pressure in part brought about by better adherence,
thereby reducing the risk of cardiovascular disease. They
also reduce the risk of new onset type 2 diabetes. Such
outcomes are associated with significant associated
costs. Therefore, in patients with hypertension and
MetS, some of the drug costs of newer antihypertensive
medications will be balanced by costs saved from redu-
cing these negative outcomes. The magnitude of these
Table 3 Sensitivity analysis, total annual cost-of-illness (Euros, millions) of hypertension in the presence and absence
of MetS; 2008
Germany Spain Italy
Baseline
Presence 24,427 1,908 4,877
Absence 5,341 2,683 5,956
Type 2 diabetes; including only incident type 2 diabetes
Presence 8,753 1,050 1,775
Absence 3,382 2,115 3,876
Proportion treated; assume 58% hypertensive subjects were treated in Spain
Presence NA 2,010 NA
Absence NA 3,058 NA
Continuation rate; vary by 20% above/below the mean
+ 20% Presence 24,418 1,913 4,895
+ 20% Absence 5,357 2,707 6,035
- 20% Presence 24,406 1,898 4,850
- 20% Absence 5,302 2,635 5,831
Costs; vary by 20% above/below the mean
Drug costs
+ 20% Presence 24,553 1,928 4,929
+ 20% Absence 5,423 4,329 6,147
- 20% Presence 24,247 1,886 4,825
- 20% Absence 5,224 2,603 5,762
CVD costs
+ 20% Presence 25,481 2,049 5,041
+ 20% Absence 5,682 2,934 6,276
- 20% Presence 23,373 1,769 4,714
- 20% Absence 5,000 2,431 5,637
Type 2 diabetes costs
+ 20% Presence 27,743 2,102 5,573
+ 20% Absence 5,735 2,803 6,392
- 20% Presence 21,112 1,715 4,183
- 20% Absence 4,948 2,564 5,521
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hypertension and four other components of MetS will
demonstrate greater reductions in the incidence of
cardiovascular events and new cases of type 2 diabetes
and their associated costs as a result of treatment with
newer antihypertensives compared to patients with
hypertension only. Cost-effectiveness studies, asses-
sing long-term costs and outcomes, will be required
to demonstrate the incremental costs and benefits of
new versus old antihypertensives for patients with
hypertension and MetS. Studies have already demon-
strated the cost-effectiveness of ARBs and ACE-inhi-
bitors in patients at increased risk of diabetes and
heart failure [54].
Conclusion
The results of this study show that hypertensive patients
with MetS are associated with higher costs of care com-
pared to those without due to the increase in incident
cardiovascular events and prevalent cases of type 2 dia-
betes. The resource implications of MetS rise linearly
with each additional MetS component. This burden is
forecast to rise in the future as a result of the aging
population and an increase in the components of the
syndrome. Prevention and appropriate treatment of
MetS is likely to lead to a reduction in costs of care.
Newer antihypertensive medications provide better con-
trol of blood pressure leading to reduced incidence of
cardiovascular disease and type 2 diabetes. These bene-
fits will be more marked in those hypertensive subjects
who have a high number of MetS components clustered
together. Following guidelines set out for this special
group of patients, which advocate the use of newer anti-
hypertensives, are likely to lead to longer-term economic
benefits for the health service and quality of life
improvement for patients.
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